CASI Pharmaceuticals (CASIF) Total Current Liabilities (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Total Current Liabilities came in at $49.7 million in Q4 2025, up 36.26% YoY from $36.5 million in Q4 2024, and up 26.0% on a QoQ basis from $39.4 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Total Current Liabilities (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Total Current Liabilities data on file, last reported at $49.7 million in Q4 2025.
- Quarterly Total Current Liabilities rose 36.26% year-over-year to $49.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $49.7 million (up 36.26% YoY) and the FY2025 annual result came in at $49.7 million, up 36.26% from the prior year.
- Total Current Liabilities rose to $49.7 million in Q4 2025, from $39.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $33.7 billion in Q1 2025 to a low of $8.5 million in Q1 2024.
- A 5-year average of $6.6 billion and a median of $39.4 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities tumbled 99.78% — and 2025, when it jumped 394480.99%.
- Tracing CASIF's Total Current Liabilities over 5 years: stood at $13.2 million in 2021, then rose by 28.96% to $17.0 million in 2022, then surged by 98259.31% to $16.7 billion in 2023, then plunged by 99.78% to $36.5 million in 2024, then soared by 36.26% to $49.7 million in 2025.
- The last three Total Current Liabilities figures came in at $49.7 million (Q4 2025), $39.4 million (Q3 2025), and $37.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | 66.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.67 Mn |
| Sep 30, 2025 | 39.42 Mn |
| Jun 30, 2025 | 37.74 Mn |
| Mar 31, 2025 | 33.71 Bn |
| Dec 31, 2024 | 36.45 Mn |
| Jun 30, 2024 | 9.58 Bn |
| Mar 31, 2024 | 8.54 Mn |
| Dec 31, 2023 | 16.73 Bn |
| Jun 30, 2023 | 11.91 Bn |
| Dec 31, 2022 | 17.01 Mn |
| Dec 31, 2021 | 13.19 Mn |